Related Experiment Videos
CD34 selection using three immunoselection devices: comparison of T-cell depleted allografts
P V O'Donnell1, B Myers, J Edwards
1Division of Hematologic Malignancies, The Johns Hopkins Oncology Center Baltimore, MD, USA.
Cytotherapy
|April 16, 2002
Summary
Three stem cell selection devices for bone marrow transplants showed comparable clinical outcomes, despite differences in purity and processing time. Allografts engineered by these devices are suitable for T-cell depletion in bone marrow transplantation.
Area of Science:
- Hematology
- Immunology
- Transplant Science
Background:
- T-cell depletion of allografts reduces graft-versus-host disease (GvHD) after bone marrow transplantation (BMT).
- Counterflow centrifugal elutriation (CCE) combined with CD34(+) stem cell immunoselection is used for T-cell depletion.
- Comparison of commercial stem cell selection devices and their clinical impact is crucial.
Purpose of the Study:
- To compare the performance of three commercial immunoselection devices (CellPro CEPRATE, Nexell Isolex 300i, AmCell CliniMACS) for CD34(+) stem cell recovery.
- To evaluate the clinical outcomes of allografts engineered using these different devices.
Main Methods:
- Bone marrow allografts were prepared for BMT using CCE to separate lymphocyte-rich and -depleted fractions.
- CD34(+) stem cells were recovered from lymphocyte-rich fractions using CEPRATE, Isolex 300i, or CliniMACS devices.
- Allografts comprised the lymphocyte-depleted fraction plus the CD34-selected fraction.
Main Results:
- CD34(+) cell yields were similar across all three devices.
- Significant differences were observed in purity (CEPRATE < Isolex 300i < CliniMACS) and processing time (CEPRATE < CliniMACS < Isolex 300i).
- The Isolex 300i device presented more technical challenges; however, allograft composition, engraftment, and GvHD incidence were comparable across devices.
Conclusions:
- Allografts prepared using CEPRATE, Isolex 300i (v 2.5), and CliniMACS devices are comparable for clinical use in T-cell depletion strategies.
- These devices provide suitable allografts for BMT, likely applicable to direct T-cell depletion of bone marrow.